Revolution Medicines
在场
是其中之一......
Revolution Medicines 是一家在股票代码 RVMD (US) 下上市的公司。
涉及Revolution Medicines的并购和融资。
- Revolution Medicines 已收购 Eqrx (公布2023十一月10号).
高管
查看带有其 39 名主要高管的组织结构图
Revolution Medicines 搜索最多的简介
- Mark Goldsmith, President, Chief Executive Officer and Board Chair...
- Thilo Schroeder, Director
- Sushil Patel, Director
创建提醒
跟踪 Revolution Medicines 的高管变动
药店
Revolution Medicines 拥有 1,842 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- BeiGene将改名为BeOne Medicines。 (公布2024十一月15号).
- GlycoMimetics and Crescent Biopharma have announced they will merge (公布2024十一月15号)..
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
药店 行业的其他推荐联系人
消息
Revolution Medicines 的最新新闻稿
- Press Releases | Revolution Medicines
- Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition | Revolution Medicines
- Revolution Medicines Completes Acquisition of EQRx | Revolution Medicines
- Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress | Revolution Medicines
- Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023 | Revolution Medicines
- Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc. | Revolution Medicines
- Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236 | Revolution Medicines
- Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast | Revolution Medicines, Inc.
- Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting | Revolution Medicines, Inc.
- Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor | Revolution Medicines, Inc.
- View more press releases Close
通过电子邮件
